Soleil Securities upgrades TomoTherapy (Nasdaq: TOMO) from Sell to Hold. Price target $3.

Soleil analyst says, "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE